about
Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosisRecent Treatments of Interstitial Lung Disease with Systemic SclerosisThe role of biologics in treatment of connective tissue disease-associated interstitial lung diseaseRheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic patternMycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience.Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF).Imaging lung disease in systemic sclerosis.Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody.Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.Scleroderma lung diseaseInterstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung diseaseHow should we treat vascular and fibrotic lung disease in scleroderma?Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohortTreatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung diseaseCutaneous Connective Tissue Diseases: Epidemiology, Diagnosis, and Treatment.Current treatment options in systemic Sclerosis (Scleroderma).On the respiratory mechanics measured by forced oscillation technique in patients with systemic sclerosis.Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung diseaseGender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials.A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients.Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale.Predictors of end stage lung disease in a cohort of patients with sclerodermaSubmaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testComputer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysisClinical trials in systemic sclerosis: lessons learned and outcomes.Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisBronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseImmunosuppression for interstitial lung disease in systemic sclerosis - novel insights and opportunities for translational research.Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.Outcome Measures for Clinical Trials in Interstitial Lung Diseases.Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis.Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity.Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?
P2860
Q24814170-4E973B2A-9DCE-40D7-BD95-92FCFFADBAEDQ26773161-95B74F25-D907-4668-BA88-E40B45933328Q28082021-BADE7878-EE65-4831-B7A1-FD5A6838229BQ33639777-7D773937-49D3-40E3-A010-C5508B6C3EC8Q33727800-9B7AAE6E-4939-4D49-AAA6-F6AE866C2869Q33737250-4F34FD0F-E204-48AC-9694-6B03ED12FBA8Q33754571-0DB74362-1CD1-4938-9CBC-F81FD2AE0C9FQ33855883-AC047857-072F-4A3A-98C7-80F5C4E9F5EFQ33891119-FBC2537A-01E5-4F6C-AA4B-FE2F7CD90549Q33919119-3A72287E-BC14-4F09-A226-0B93F4AF8DDDQ33956830-6F56F372-AF7F-4965-9DD8-8CB8626EB6CFQ34027197-F3C27982-7E34-4AB9-BE66-65C7CFB31DB4Q34154288-8F5AD3CF-3733-4994-AA7B-BA778BC53910Q34167350-8697514F-6C63-4D66-BB0E-9EAB5B2DA6E0Q34346178-7B2AFA95-1FCE-4A23-B21E-B657CA7397ADQ34425493-DFD7491B-DEDA-4D09-B5FA-1419D0280DCDQ34466996-58DE7583-D8BB-4AD5-8C4A-1E1175B52107Q34567929-9900A8C6-52DF-41C5-8CA6-DA3A6B84C8C0Q34700520-B0217023-31DD-4B97-9E56-8806A36D96E4Q34921541-B6E86663-E4B8-441F-AECD-4740D0D4809DQ35022904-21C4584B-77B2-4F54-887D-466AF812E5D4Q35225024-BF6E0F1A-A533-4A2E-AE9E-15DB8828A526Q35242200-27040A71-438A-4734-B194-AD82D859F957Q35549965-4C42BAA6-379F-4CDF-8C42-323C04E26DD2Q35552308-856CFF26-791E-4CD7-897A-F40DA418F890Q35638700-9E6B8D3D-43C3-4F44-965D-B4E2E88ABF8EQ35941472-CD98028B-C6C8-4DC7-A5E5-2065B0724B72Q35977704-B3C9CDEB-F984-42B8-BDE0-8A2B1F0A6BFBQ36130965-9B8E2EE2-B29C-4C8C-9BB7-8F303F259A3BQ36145795-9BC0B88E-AE03-4596-9A51-7626C57D568AQ36171822-F50D9C79-CB47-4C54-AC1E-B575DCC75B89Q36330650-23F78946-0825-4862-96C3-F0275BC7FE40Q36398275-A622961D-4965-4BBF-A5AF-95F806D665D4Q36543145-88CC5915-76EA-45E1-AD1E-FE1AB03C82BDQ36645934-525DC345-800B-40B4-8360-98A8AAAC4D31Q36726418-E1131222-628E-42F6-B098-86F86418D89DQ37003312-E5570BEE-822C-4B94-B35D-9C9508D4D033Q37058565-68561779-4445-45F1-A92C-90735C5AF33CQ37197313-91A79020-B263-4665-A8CB-98974E96AA33Q37276787-45CAD9EE-C557-4EF4-8885-F8D68F9BD04F
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Severe restrictive lung disease in systemic sclerosis.
@en
Severe restrictive lung disease in systemic sclerosis.
@nl
type
label
Severe restrictive lung disease in systemic sclerosis.
@en
Severe restrictive lung disease in systemic sclerosis.
@nl
prefLabel
Severe restrictive lung disease in systemic sclerosis.
@en
Severe restrictive lung disease in systemic sclerosis.
@nl
P2093
P2860
P356
P1476
Severe restrictive lung disease in systemic sclerosis.
@en
P2093
P2860
P304
P356
10.1002/ART.1780370903
P577
1994-09-01T00:00:00Z